Viking Therapeutics, Inc. (VKTX) Earnings Call Transcripts
Viking Therapeutics, Inc.'s Latest Earnings Call - June 4, 2026
In the Q2 2026 earnings call, Viking Therapeutics (VKTX) provided an update on its obesity program, which is in Phase III development with two trials (VANQUISH-1 and VANQUISH-2) fully enrolled and expected to read out data in the second half of 2027. Management highlighted the upcoming initiation of Phase III trials for an oral formulation of the same compound, which could represent a significant advancement in the GLP-1/GIP co-agonist market. The company ended the quarter with over $600 million in cash, indicating strong financial health to support ongoing and future clinical trials.
Reported metrics
| Metric | Value |
|---|---|
| Cash Position | $600M (positive) |
| Phase III Trials | 2 (positive) |
| Oral Phase III Trials | 1 (positive) |
| Maintenance Study Readout | Q3 2026 (positive) |
| Market Share Target | 5%-10% (neutral) |
| Half-Life of Compound | 8-10 days (positive) |
Guidance from management
Management is confident in the upcoming Phase III trials and the potential for the oral formulation to capture market share. They indicated that the cash position allows for continued investment in clinical development through early 2028.
What management said
Yes. So with the subcu, we think the Phase III data, we're looking at rough estimate here, second half '27. The oral, I think of that as always about 12 to 18 months behind the subcu. So the cadence of the subcu data, we would expect the VANQUISH-1 study to read out first since that was enrolled first, and then VANQUISH-2 to read out second. And then with the oral, I don't know, if they enroll at the exact same rat...
Yes, yes. So the titration, we haven't disclosed the doses yet for the oral, but the titration period will be shorter with the oral formulation. There will be fewer titration steps. So that means fewer weeks to get to that 52-week steady treatment phase of the study. So overall, the subcu trials are 78 weeks. The oral studies will be shorter than that. And they're also smaller, but probably 75% smaller overall for ...
What analysts pressed on
Analysts expressed concerns about the feasibility of managing multiple Phase III trials simultaneously given the company's size. There were also questions regarding the potential risks associated with transitioning dosing regimens and the impact on tolerability.
Main topics on the call
- Phase III Trials Update — Viking is advancing its obesity program with two Phase III trials (VANQUISH-1 and VANQUISH-2) fully enrolled, expecting data readouts in the second half of 2027. Management stated, 'we think the half-life should support ...
- Oral Formulation Development — The company plans to initiate Phase III trials for an oral formulation of its GLP-1/GIP co-agonist later this year, which management believes could be the first oral formulation in this category. This was supported by th...
- Maintenance Study Insights — A maintenance study is set to read out in Q3 2026, exploring less frequent dosing regimens. Management noted, 'if everything works well, we could take anything that looks attractive from the maintenance study and then im...
- Financial Position — Viking ended Q1 2026 with over $600 million in cash, which is expected to fund operations through early 2028. CFO Gregory Zante emphasized, 'we have a very efficient cash spend footprint at the company.'
Read the full Viking Therapeutics, Inc. transcript (June 4, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (VKTX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 42 calls on record spanning February 26, 2020 to July 29, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 42 Viking Therapeutics, Inc. earnings call transcripts on record, spanning February 26, 2020 to July 29, 2026. Based on this history, Viking Therapeutics, Inc. reports quarterly. The most recent call on file is dated July 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- VKTX
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 42
- First call
- February 26, 2020
- Most recent
- July 29, 2026
- Reporting cadence
- quarterly